Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Patients with Advanced Lung Adenocarcinoma and Complex EGFR Mutations Demonstrate Different Response Rates to TKI Therapy

By European Society for Medical Oncology | April 13, 2018

Findings from a large retrospective analysis presented at the European Lung Cancer Congress (ELCC) 2018, held 11 to 14 April in Geneva, Switzerland revealed that patients with advanced lung adenocarcinoma and complex epidermal growth factor receptor (EGFR) mutations demonstrated quite different response rates to standard first-generation tyrosine kinase inhibitor (TKI) treatment.

Patients with advanced lung adenocarcinomas can harbour complex mutations, such as two or more different EGFR mutations, within a single tumour sample, according to Bo Zhang of the Pulmonary Department, Shanghai Chest Hospital in Shanghai, China.

Whether the presence of complex mutations altered the efficacy of standard first-line treatment with TKIs was unknown. In addition, the frequency of complex mutations was also undocumented.

For this retrospective analysis, Dr. Zhang and colleagues recruited consecutive patients diagnosed with lung adenocarcinoma and an EGFR mutation from January 2011 to January 2017, and reviewed the efficacy of TKI treatment in patients with complex mutations.

Response to TKIs varies greatly according to EGFR mutation type

Of the 16,840 subjects that underwent screening, 5898 patients were positive for EGFR mutations. Complex mutations were diagnosed in 187 patients for a frequency of 3.2% in the EGFR mutant patients. Of these patients, 95 had advanced lung adenocarcinoma and were treated with TKIs.

While the 27 patients with adenocarcinoma with Del-19+21L858R mutation demonstrated an objective response rate (ORR) of 72.7% with TKI treatment, 28 patients with Del-19/21L858R+ atypical mutations had an ORR of 54.2%. Twenty patients with double atypical mutations had an ORR of 66.7% following TKI treatment.

Median progression-free survival (PFS) in the respective cohorts was 18.2 months (95% confidence interval [CI] 12.0, 24.4), 10.1 months (95% CI 6.5, 13.7), and 11.1 months (95% CI 6.8,15.4).

The poorest response was seen in 20 patients having tumours harbouring complex mutations with primary drug-resistant pattern who demonstrated an ORR of 15.0% with TKI treatment. Median PFS in these patients was just 1.4 (95% CI 0.2, 2.5) months.

Dr Sandra Ortiz-Cuaran, who discussed the poster data, said that complex EGFR mutations account for 3.2% of the entire EGFR mutation spectrum. Patients with double classical mutations had the best PFS compared with other mutation types and may benefit more from TKIs treatment. Those who harboured complex mutations with classical pattern or double atypical mutations derived similar PFS compared with individuals who had single classical mutation. 

Conclusions

The authors stated that first generation EGFR–TKI therapy is effective in patients with Del-19+21L858R, Del-19/21L858R+atypical mutations, and double atypical mutations. However, TKI treatment was less effective in patients with complex mutations and primary drug–resistant pattern. 


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE